HIGHLIGHTS
- who: Top from the Department of Internal Medicine , Hematology and Oncology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany have published the article: Characterization of CD4+ T cells primed and boosted by MHCII, in the Journal: (JOURNAL)
- what: The authors showed the capability of the Mel202/DR1/CD80 vaccine cells to directly prime and boost a diverse repertoire of highly purified, nau00efve CD4+ T_cells isolated from PBMC. The authors show that this strategy could be applied for PBMC in combination with MHC II uveal melanoma cell-based vaccines and cytokine support. The . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.